Nutriband Inc. (NASDAQ:NTRB) Short Interest Update

Key Points

• Nutriband Inc. experienced a significant decline in short interest, decreasing by 21.1% in August to a total of 125,400 shares.
• The company's latest earnings report showed a loss of ($2.12) per share, which was significantly below the consensus estimate of ($0.17), and a revenue of $0.62 million.
• Analysts have downgraded Nutriband's stock rating from a "hold" to a "strong sell," with an average price target of $13.00.

Nutriband Inc. (NASDAQ:NTRB - Get Free Report) saw a significant drop in short interest during the month of August. As of August 31st, there was short interest totaling 125,400 shares, a drop of 21.1% from the August 15th total of 159,000 shares. Based on an average trading volume of 115,300 shares, the days-to-cover ratio is presently 1.1 days. Currently, 2.3% of the company's shares are short sold. Currently, 2.3% of the company's shares are short sold. Based on an average trading volume of 115,300 shares, the days-to-cover ratio is presently 1.1 days.

Nutriband Price Performance

Shares of NTRB stock traded up $0.09 during trading hours on Monday, hitting $7.31. The company's stock had a trading volume of 15,221 shares, compared to its average volume of 129,478. The stock has a market cap of $87.89 million, a price-to-earnings ratio of -2.55 and a beta of 1.13. The business has a fifty day moving average of $7.04 and a 200-day moving average of $6.70. Nutriband has a twelve month low of $3.72 and a twelve month high of $11.78. The company has a current ratio of 4.78, a quick ratio of 4.70 and a debt-to-equity ratio of 0.01.

Nutriband (NASDAQ:NTRB - Get Free Report) last posted its earnings results on Tuesday, September 9th. The company reported ($2.12) earnings per share for the quarter, missing the consensus estimate of ($0.17) by ($1.95). The business had revenue of $0.62 million for the quarter, compared to analyst estimates of $0.71 million. Nutriband had a negative net margin of 398.29% and a negative return on equity of 85.40%. As a group, equities research analysts anticipate that Nutriband will post -0.6 EPS for the current year.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in Nutriband stock. US Bancorp DE bought a new position in shares of Nutriband Inc. (NASDAQ:NTRB - Free Report) in the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm bought 4,798 shares of the company's stock, valued at approximately $29,000. Hedge funds and other institutional investors own 19.70% of the company's stock.

Analyst Upgrades and Downgrades

Separately, Zacks Research cut Nutriband from a "hold" rating to a "strong sell" rating in a research note on Tuesday, September 16th. One investment analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of "Hold" and a consensus price target of $13.00.

Nutriband Company Profile

Nutriband Inc develops a portfolio of transdermal pharmaceutical products. Its lead product in development is AVERSA fentanyl, an abuse deterrent fentanyl transdermal system that provides clinicians and patients with an extended-release transdermal fentanyl product for use in managing chronic pain requiring around the clock opioid therapy.